A multicenter study of the immunogenicity % safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose
Rotavirus Vaccine
Infections, Rotavirus
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided.
March 2017